SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kos Pharmaceuticals, Inc (KOSP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tom D who wrote (12)9/2/1997 11:24:00 AM
From: James Silverman   of 118
 
I have noticed the patent expiration. On the flip side, I do not think Niaspan will be all that easy to reproduce and hence don't expect generic competition for some time after the expiration. They also can easily use FDA legal guidelines and sue any potential knockoff, further delaying a generic release. I can only guess that worst case scenario a generic could hit the market 3-4 years _after_expiration, factoring in legal wrangling.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News